Pay in 4 interest-free payments of $5.49 Learn more
Ships within 48 hours · Estimated delivery Oct 15 - Oct 20
What you see is what you get
2.1.8 Ropsacitinib Ropsacitinib (PF-06826647) is a selective TYK2 inhibitor that was evaluated in, a Phase 2B double-blind, placebo-controlled RCT with an open-label extension (NCT04209556) designed to assess its safety and efficacy in participants with moderate to severe UC
Evol Med Public Health
Moore Simas TA, Waring ME, Sullivan GM, Liao X, Rosal MC, Hardy JR, et al
Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis [PMID: 40834310] Laboratory literature summary: Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis
US$ 24.50
US$ 27.20
US$ 29.20
US$ 28.24
US$ 27.89
US$ 29.13
US$ 29.62
US$ 26.91
